Skip to main content Skip to navigation

Professor of Clinical Pharmacology at University of Warwick backs Alzheimer's drug U-turn by NICE

Professor Donald Singer, Professor of Clinical Pharmacology and Therapeutics at the University of Warwick has spoken in today's (7) Daily Telegraph in support of new plans to allow access to drugs for patients in the early stages of Alzheimer's disease.

Current rules prevent doctors prescribing three drugs, donepezil, galantamine and rivastigmine, in early cases of the disease. However, the National Institute for Health and Clinical Excellence (NICE)  now says evidence backs the use of drugs for mild symptoms.

Professor Donald Singer said: "The proposal by NICE to extend its guidance to include access for 3 drugs (donepezil, galantamine and rivastigimine) to patients with much milder disease than previously eligible is excellent news for patients with Alzheimer's disease and their families. It is also very encouraging to have in the guidance a new treatment option (memantine) for patients with more severe disease.

 "People with serious conditions such as Alzheimer's may naturally express concern about how long this has taken. However it is essential that health policy makers have convincing evidence both for effectiveness and risk before making a medicine available to people who could benefit. Consider the recent public concern about regulation of the diabetes drug rosiglitazone, for which an unexpected increase in cardiovascular risk appears to have occurred after it became widely available. It will still be very important to remain vigilant for possible unexpected risks of the Alzheimer's treatments, as these drugs will now be exposed to large numbers of people, who may also be medically more complex, and therefore more at risk of adverse effects, than in the clinical trials on which the NICE guidance has been based."